Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised medicine.
Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions (56 drug combinations x 20 replicates) on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments. This research, incorporating fundamental science alongside clinical expertise at Aachen University Hospital, was led by EMBL group leader Christoph Merten and Julio Saez-Rodriguez, former group leader at EMBL-EBI and now Professor at Heidelberg University.
Small biopsies, many drugs
Directly testing multiple cancer drugs on biopsies – parts of the tumour which have been taken from a patient – is a powerful way to discover which drugs work best, and for whom. This is because depending on the specific tumour characteristics, cancer therapies can be more effective in some people than others. However, large-scale patient specific drug screenings have so far been limited by the small biopsy size that can typically be obtained from patients. That is why in the current paper, the team developed a miniaturised device which can test more drugs on a limited number of cells.
Tailored therapies
The research team initially tested 56 drug combinations on two different human cancer cell types grown in the lab. Drug combinations which killed both types of cancer cells were thought to be potentially toxic and thus unsafe for further testing. However, some drug combinations which targeted and killed only one type of cancer cell were found to be more effective than standard clinical therapies which only use one drug. These results were highly reproducible and could be validated in mouse models of human cancer.
Subsequently, cells from four cancer patient biopsies were applied to the microfluidic device and different drug combinations were tested. “We found that each individual cancer responded best to a different combination of drugs, highlighting the urgent need for patient-specific therapies,” says Federica Eduati, joint first author on the paper alongside Ramesh Utharala who designed and developed the microfluidic device.
“Before we transfer this technology into the clinics, we need to repeat these experiments in larger-scale mouse studies to understand which types of cancer this technology works best in,” says Christoph Merten. “Still, this is an exciting ‘proof of principle’ collaboration between scientists and clinicians, and we have shown that these tests can be run quickly and for less than $150 USD per patient.”
Learn more: Miniature testing of drug pairs on tumour biopsies
The Latest on: Personalized medicine
[google_news title=”” keyword=”personalized medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized medicine
- Personalized 'cocktails' of antibiotics, probiotics and prebiotics hold promise in treating IBS, pilot study findson April 26, 2024 at 3:10 pm
Personalized "cocktails" of antibiotics, probiotics and prebiotics hold great promise in the treatment of a common form of irritable bowel syndrome (IBS), according to research presented at the ESCMID ...
- 'Despite promise, personalized medicine for head and neck cancers facing hurdles'on April 26, 2024 at 3:45 am
Improved efficacy: By identifying specific mutations driving tumour growth, personalized medicine allows for targeted therapies that have a higher success rate compared to ‘one-size-fits-all’ ...
- Examining the impact of gene-based breeding on agriculture and medicineon April 25, 2024 at 10:22 am
A research team has demonstrated that gene-based breeding (GBB) offers a transformative approach to advancing plant and animal breeding, showing remarkable predictability, speed, and ...
- Calories, gut health and food as medicine — with AdventHealth’s Karen Corbin and a local culinary medicine specialist (podcast)on April 24, 2024 at 9:00 pm
In this episode of the Inspiring Wholeness podcast, AdventHealth’s Karen Corbin and Allison Harrell, sole practitioner and culinary medicine specialist, discuss calories, gut health and food as ...
- AI could predict whether cancer treatments will work, experts say: ‘Exciting time in medicine'on April 23, 2024 at 3:00 am
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.
- 8 Clinical Trials That Will Shape Medicine in 2024on April 22, 2024 at 10:13 am
One of the exciting things about modern medicine is that it is making increasingly rapid advancements in a number of key areas. These advancements could have a major impact on the future of medicine.
- Progesterone Therapy in Demand for Personalized Medicine: Market to Reach US$4.8 Billion by 2034 | Future Market Insights, Inc.on April 22, 2024 at 3:30 am
After extensive research, the progesterone market suggests an upward trajectory from 2024 to 2034, inferring a healthy CAGR of 12.30%. With preliminary valuations of US$ 1.50 billion in 2024, the ...
- How AI can help cancer patients receive personalized and precise treatment fasteron April 16, 2024 at 1:35 pm
Providence and Microsoft are developing research prototype AI tools to sort through growing mountains of patient data.
- The Future of Breast Cancer Care: Blackwood on Personalized Approacheson April 15, 2024 at 8:01 am
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
via Bing News